Posts

Trial of Ritlecitinib in Alopecia Areata

Trial of Ritlecitinib in Alopecia Areata

/in /by

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Pfizer Inc today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by an immune attack on the hair follicles that causes hair loss on the scalp and can also affect the face and body.1,2

Ritlecitinib 50 mg and 30 mg achieved the primary efficacy endpoint of the study, namely the proportion of patients with less than or equal to 20 per cent scalp hair loss after six months of treatment versus placebo.

European Medicines Agency approved treatments,” said Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “We look forward to bringing this potential new treatment option to patients living with alopecia areata as soon as possible.”

The Phase 2b/3 ALLEGRO trial met the primary efficacy endpoint of improving scalp hair regrowth. All participants entered the study with at least 50 per cent scalp hair loss due to alopecia areata, as measured by the Severity of Alopecia Tool (SALT) score.

A statistically significantly greater proportion of patients who took ritlecitinib 30 mg or 50 mg once-daily, with or without a four-week initial treatment of 200 mg once-daily, had 20 per cent or less scalp hair loss (an absolute SALT score ≤20) after 24 weeks of treatment compared with placebo.

This was followed by a 24-week extension period, during which all participants initially randomized to receive ritlecitinib continued on the same regimen, while participants who received placebo during the initial 24 weeks advanced to one of two regimens: 200 mg for four weeks followed by 50 mg for 20 weeks, or 50 mg for 24 weeks. The study also included a 10 mg dosing arm, which was assessed for dose-ranging and was not tested for statistically significant efficacy compared to placebo.

The safety profile seen with ritlecitinib was consistent with previous studies. Overall, the percentage of patients with adverse events (AEs), serious AEs and discontinuing due to AEs was similar across all treatment groups.

The most common AEs seen in the study were nasopharyngitis, headache and upper respiratory tract infection. There were no major adverse cardiac events (MACE), deaths or opportunistic infections in the trial. Eight patients who were treated with ritlecitinib developed mild to moderate herpes zoster (shingles).

There was one case of pulmonary embolism in the ritlecitinib 50 mg group, which was reported to have occurred on Day 169. There were two malignancies (both breast cancers) reported in the ritlecitinib 50 mg group, which were reported to have occurred on Day 68 and Day 195. Both participants were discontinued from the study.

Full results from this study will be submitted for future scientific publication and presentation. These data, together with data that will become available from ALLEGRO-LT, will form the basis for planned future regulatory filings.

Ritlecitinib is the first in a new investigational class of covalent kinase inhibitors that have high selectivity for Janus kinase 3 (JAK3) and members of the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In laboratory studies, ritlecitinib has been shown to block the activity of signalling molecules and immune cells believed to contribute to loss of hair in people with alopecia areata.3

Ritlecitinib, which was granted Breakthrough Therapy designation from the U.S. FDA for the treatment of alopecia areata in September 2018, is also being evaluated for vitiligo, rheumatoid arthritis, Crohn’s disease and ulcerative colitis.

About the Phase 2b/3 ALLEGRO Trial

This randomized, placebo-controlled, double-blind study investigated ritlecitinib in patients 12 years of age and older with alopecia areata (n=718). Patients included in the study had 50 per cent or more hair loss of the scalp, including patients with alopecia totalis (complete scalp hair loss) and Alopecia Universalis (complete scalp, face and body hair loss), and were experiencing a current episode of alopecia areata that had lasted between six months and ten years. Patients were randomized to receive ritlecitinib 50 mg or 30 mg (with or without one month of initial treatment with once-daily ritlecitinib 200 mg), ritlecitinib 10 mg or placebo.

The primary endpoint was the proportion of patients with scalp hair regrowth in response to ritlecitinib treatment, based on an absolute SALT Score ≤20 at Week 24. SALT is a tool that measures the amount of scalp hair loss. The tool divides the scalp into standard regions, and each region contributes to the total SALT score, which ranges from 0 to 100. A SALT score of 0 corresponds to no scalp hair loss, while a SALT score of 100 corresponds to a total lack of hair on the scalp.4

More information about the Phase 2b/3 ALLEGRO trial can be found at https://www.clinicaltrials.gov under the identifier NCT03732807.

About Alopecia Areata

Alopecia areata is an autoimmune disease characterized by patchy hair loss, almost always involving the scalp, but sometimes also involving the face (eyebrows, eyelashes, beard), the whole scalp or the whole body.1,2 People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out.1,2 The mean age of onset is between 25 and 35 years, but it can also impact older adults, children and adolescents, and is seen in both sexes and all ethnicities.1,2 Alopecia areata is associated with poor health-related quality of life for many patients, who may suffer from serious psychological consequences, including depression and anxiety.1

1 Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clinical, Cosmetic and Investigational Dermatology. 2015;8:397-403. doi:10.2147/CCID.S53985.

2 Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nature reviews Disease primers. 2017;3:17011. doi:10.1038/nrdp.2017.11.

3 King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021 Mar 20:S0190-9622(21)00601-0. doi: 10.1016/j.jaad.2021.03.050.

4 Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines–part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440-447.

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Source

Recent Posts

Trial of Ritlecitinib in Alopecia Areata

Trial of Ritlecitinib in Alopecia Areata

/in /by

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Pfizer Inc today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by an immune attack on the hair follicles that causes hair loss on the scalp and can also affect the face and body.1,2

Ritlecitinib 50 mg and 30 mg achieved the primary efficacy endpoint of the study, namely the proportion of patients with less than or equal to 20 per cent scalp hair loss after six months of treatment versus placebo.

European Medicines Agency approved treatments,” said Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “We look forward to bringing this potential new treatment option to patients living with alopecia areata as soon as possible.”

The Phase 2b/3 ALLEGRO trial met the primary efficacy endpoint of improving scalp hair regrowth. All participants entered the study with at least 50 per cent scalp hair loss due to alopecia areata, as measured by the Severity of Alopecia Tool (SALT) score.

A statistically significantly greater proportion of patients who took ritlecitinib 30 mg or 50 mg once-daily, with or without a four-week initial treatment of 200 mg once-daily, had 20 per cent or less scalp hair loss (an absolute SALT score ≤20) after 24 weeks of treatment compared with placebo.

This was followed by a 24-week extension period, during which all participants initially randomized to receive ritlecitinib continued on the same regimen, while participants who received placebo during the initial 24 weeks advanced to one of two regimens: 200 mg for four weeks followed by 50 mg for 20 weeks, or 50 mg for 24 weeks. The study also included a 10 mg dosing arm, which was assessed for dose-ranging and was not tested for statistically significant efficacy compared to placebo.

The safety profile seen with ritlecitinib was consistent with previous studies. Overall, the percentage of patients with adverse events (AEs), serious AEs and discontinuing due to AEs was similar across all treatment groups.

The most common AEs seen in the study were nasopharyngitis, headache and upper respiratory tract infection. There were no major adverse cardiac events (MACE), deaths or opportunistic infections in the trial. Eight patients who were treated with ritlecitinib developed mild to moderate herpes zoster (shingles).

There was one case of pulmonary embolism in the ritlecitinib 50 mg group, which was reported to have occurred on Day 169. There were two malignancies (both breast cancers) reported in the ritlecitinib 50 mg group, which were reported to have occurred on Day 68 and Day 195. Both participants were discontinued from the study.

Full results from this study will be submitted for future scientific publication and presentation. These data, together with data that will become available from ALLEGRO-LT, will form the basis for planned future regulatory filings.

Ritlecitinib is the first in a new investigational class of covalent kinase inhibitors that have high selectivity for Janus kinase 3 (JAK3) and members of the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In laboratory studies, ritlecitinib has been shown to block the activity of signalling molecules and immune cells believed to contribute to loss of hair in people with alopecia areata.3

Ritlecitinib, which was granted Breakthrough Therapy designation from the U.S. FDA for the treatment of alopecia areata in September 2018, is also being evaluated for vitiligo, rheumatoid arthritis, Crohn’s disease and ulcerative colitis.

About the Phase 2b/3 ALLEGRO Trial

This randomized, placebo-controlled, double-blind study investigated ritlecitinib in patients 12 years of age and older with alopecia areata (n=718). Patients included in the study had 50 per cent or more hair loss of the scalp, including patients with alopecia totalis (complete scalp hair loss) and Alopecia Universalis (complete scalp, face and body hair loss), and were experiencing a current episode of alopecia areata that had lasted between six months and ten years. Patients were randomized to receive ritlecitinib 50 mg or 30 mg (with or without one month of initial treatment with once-daily ritlecitinib 200 mg), ritlecitinib 10 mg or placebo.

The primary endpoint was the proportion of patients with scalp hair regrowth in response to ritlecitinib treatment, based on an absolute SALT Score ≤20 at Week 24. SALT is a tool that measures the amount of scalp hair loss. The tool divides the scalp into standard regions, and each region contributes to the total SALT score, which ranges from 0 to 100. A SALT score of 0 corresponds to no scalp hair loss, while a SALT score of 100 corresponds to a total lack of hair on the scalp.4

More information about the Phase 2b/3 ALLEGRO trial can be found at https://www.clinicaltrials.gov under the identifier NCT03732807.

About Alopecia Areata

Alopecia areata is an autoimmune disease characterized by patchy hair loss, almost always involving the scalp, but sometimes also involving the face (eyebrows, eyelashes, beard), the whole scalp or the whole body.1,2 People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out.1,2 The mean age of onset is between 25 and 35 years, but it can also impact older adults, children and adolescents, and is seen in both sexes and all ethnicities.1,2 Alopecia areata is associated with poor health-related quality of life for many patients, who may suffer from serious psychological consequences, including depression and anxiety.1

1 Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clinical, Cosmetic and Investigational Dermatology. 2015;8:397-403. doi:10.2147/CCID.S53985.

2 Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nature reviews Disease primers. 2017;3:17011. doi:10.1038/nrdp.2017.11.

3 King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021 Mar 20:S0190-9622(21)00601-0. doi: 10.1016/j.jaad.2021.03.050.

4 Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines–part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440-447.

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Source

Recent Posts

Anti-dandruff Agent Additive Market

Anti-dandruff Agent Additive Market

/in /by

Global Anti-dandruff Agent Additive Market Insights and Forecast to 2027

Market Analysis and Insights: Global Anti-dandruff Agent Additive Market

The global Anti-dandruff Agent Additive market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

Global Anti-dandruff Agent Additive Scope and Segment

Anti-dandruff Agent Additive market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Anti-dandruff Agent Additive market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2016-2027.

The following manufacturers are covered in this report:

Clariant AG

Aurora Chemical

Spec Chem Group

Kumar Organic

Chemspec Chemicals

3C Pharmchem

Somu Group

Kolon Life Science

Regen Chemical

Symrise

Tinci Materials

Seqens SAS

Merck KGaA

Plater Group

Gaopeng Pharmaceutical

Kavya Pharma

Fengchen Technology

Xi’an Taicheng Chem

Anti-dandruff Agent Additive Breakdown Data by Type

Piroctone Olamine

Climbazole

Slaicylic Acid

Ketoconazole

Coal Tar

Selenium Sulfide

Other

Anti-dandruff Agent Additive Breakdown Data by Application

Personal Care

Pharmaceutical

Regional and Country-level Analysis

The Anti-dandruff Agent Additive market is analysed and market size information is provided by regions (countries).

The key regions covered in the Anti-dandruff Agent Additive market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the United States, Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.

The report includes a country-wise and region-wise market size for the period 2016-2027. It also includes market size and forecast by Type, and Application segment in terms of production capacity, price and revenue for the period 2016-2027.

Global Anti-dandruff Agent Additive Market Insights and Forecast to 2027

Source

Recent Posts

Hair Restoration Expert Dr Epstein

Hair Restoration Expert Dr Epstein

/in /by

Hair Restoration Expert Dr. Jeffrey S. Epstein Featured in Luxury Guide Miami Summer 2021 Issue

The Foundation for Hair Restoration, the Miami-based accredited facility that is recognized for performing thousands of natural-looking surgical and non-surgical hair restoration procedures, announced today that their Founder and Director Dr. Jeffrey S. Epstein, MD, FACS, FISHRS, is being featured in the Luxury Guide Miami Summer 2021 Beauty and Wellness issue.

The feature will include a spotlight on Dr. Epstein’s work as a world expert in hair restoration. Since 1994, Dr. Epstein has been treating men and women with hair loss, performing surgical and non-surgical procedures to restore eyebrows and beards, lower hairlines, create natural-appearing full hairlines, and perform corrective procedures for patients who have had unsatisfactory results from other providers.

To date, Dr. Epstein and his team of experienced professionals have performed 15,000 hair restoration procedures for domestic patients from 50 states and international patients from over 40 countries.

“Our work is our passion.” Said Dr. Epstein. “It’s an honor to be featured in the guide alongside Miami’s finest professionals in all service areas. We always strive to provide world-class service to our patients and being featured in the summer guide is an excellent opportunity to educate discerning patients about the options available for hair restoration.”

At his practice, Dr. Epstein performs all hair restorations personally but is aided by a team of professionals including Dr. Anthony Bared, consultative services from European plastic surgeon Dr. Gorana Kuka Epstein, two nurse practitioners, and extended full-time support staff.

In addition to performing FUE (Follicular Unit Extraction) hair transplants including a no-shave approach that permits patients to be presentable the very same day, procedures which Dr. Epstein and his team can perform using 2600 grafts or more without issue, Dr. Epstein also dedicates his time as a Voluntary Assistant Professor at the University of Miami and writes at length and lectures on emerging hair restoration treatments including hairline lowering surgery and cell-based therapies.

His long list of achievements and recognitions include consistently being selected as one of the Best Doctors in America and regularly being awarded the distinction of a Castle Connelly Top Doctor. Dr. Epstein is a board-certified surgeon who holds credentials from the American Board of Facial Plastic & Reconstructive Surgery, the American Board of Hair Restoration Surgery, and the American Board of Otolaryngology. He is also the past President of the Florida Society of Facial Plastic & Reconstructive Surgery and has over 25 years of experience as a specialist in hair restoration and facial plastic surgery.

For more information on Dr. Epstein and The Foundation for Hair Restoration, visit http://www.foundhair.com. To book a consultation, write to info@foundhair.com

About Dr. Epstein

Dr. Jeffrey S. Epstein, MD, FACS, FISHRS, is considered one of the world’s most respected experts in hair restoration. He is the Founder and Director of The Foundation for Hair Restoration in Miami, an accredited and highly regarded medical facility serving domestic and international patients.

Hair Restoration Expert Dr. Jeffrey S. Epstein Featured in Luxury Guide Miami Summer 2021 Issue

Source

Recent Posts

HairMax Density Hair Care System

Hair Loss & Growth Treatments

/in /by

Global Hair Loss & Growth Treatments and Products Market Growth 2021-2026

According to this latest study, the 2021 growth of Hair Loss & Growth Treatments and Products will have significant change from the previous year.

By the most conservative estimates of global Hair Loss & Growth Treatments and Products market size (a most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 3238 million in 2020.

Over the next five years, the Hair Loss & Growth Treatments and Products market will register a 5.8% CAGR in terms of revenue, the global market size will reach US$ 4058.6 million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of Hair Loss & Growth Treatments and Products market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.

Hair Loss and Growth Devices

Shampoos and Conditioners

Medicine Product

Others

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.

Men

Women

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.

L’Oreal

Unilever

Taisho

Henkel

Merck

Shiseido

Johnson & Johnson Consumer

Rohto

Lifes2Good

Gerolymatos International

Toppik

Nanogen

Oxford BioLabs

Ultrax Labs

Avalon Natural Products

Bayer

Pharma Medico

Kirkland Signature

Phyto Ales

Amplixin

Kerafiber

Phyto

Keranique

DS Healthcare

Kaminomoto

Softto

Bawang

Zhang Guang 101

Global Hair Loss & Growth Treatments and Products Market Growth 2021-2026

Source

Recent Posts

US Hair Transplant Procedure

Global OTC Hair Loss Treatments Market

Global OTC Hair Loss Treatments Market

/in /by

Global OTC Hair Loss Treatments Market

The OTC Hair Loss Treatments is expected to grow from USD XX.0 million in 2018 to USD XX.0 million by 2025, at a Compound Annual Growth Rate (CAGR) of XX.0% during the forecast period.

The research provides insights for the global OTC Hair Loss Treatments market based on different Types, End-Users and Regions, and competitive landscape of these segments are analyzed in detail.

A wide range of market influence factors are taken into consideration in the analysis, and potential developing factors for different Types, End-Users and Regions are also included in the report in order to figure out the most promising development trends in the OTC Hair Loss Treatments industry.

For presenting the most potential investment fields in North America, Europe, Asia Pacific and Latin America, Middle East & Africa, the market capacity and consumption potential of more than 34 major powers are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

The Snapshot of Global OTC Hair Loss Treatments Market Segmentations:

By Players:

  • Merck
  • J&J
  • Taisho Pharma
  • Costco Wholesale
  • Wal-Mart
  • Bayer
  • Zhejiang Wansheng Pharma
  • Sichuan Medco Huakang Pharma
  • Zhendong Anter
  • DrFormulas
  • Renata
  • DrRPFLEGER
  • DS Healthcare Group

By Types:

  • Minoxidil
  • Procapil
  • Other

By End-User:

  • Male
  • Female

By Regions:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • UK
  • France
  • Italy
  • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)
  • Spain
  • Belgium
  • Poland
  • Russia
  • Turkey
  • Others

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia and New Zealand
  • ASEAN Countries (Indonesia, Thailand, Malaysia, Singapore, Philippines, Vietnam, Others)

Latin America, Middle East & Africa

  • GCC Countries (Saudi Arabia, United Arab Emirates, Qatar, Others)
  • Brazil
  • Nigeria
  • South Africa
  • Argentina
  • Others

Global OTC Hair Loss Treatments Market

Source

Recent Posts

Global OTC Hair Loss Treatment

/in /by

2015-2025 Global OTC Hair Loss Treatments Market Research

Summary

The global OTC Hair Loss Treatments market is expected to reach xxx Million USD by 2025, with a CAGR of xx% from 2020 to 2025.

Further key aspects of the report indicate that:
Chapter 1: Market Definition and Segment by Type, End-Use & Major Regions Market Size
Chapter 2: Global Production & Consumption Market by Type and End-Use
Chapter 3: Europe Production & Consumption Market by Type and End-Use
Chapter 4: America Production & Consumption Market by Type and End-Use
Chapter 5: Asia Production & Consumption Market by Type and End-Use
Chapter 6: Oceania Production & Consumption Market by Type and End-Use
Chapter 7: Africa Production & Consumption Market by Type and End-Use
Chapter 8: Global Market Forecast by Type, End-Use and Region
Chapter 9: Company information, Sales, Cost, Margin, news etc.
Chapter 10: Market Competition by Companies and Market Concentration Ratio
Chapter 11: Market Impact by Coronavirus.
Chapter 12: Industry Summary
.
Market Segment as follows:

Key Companies
Merck
J&J
Taisho Pharma
Costco Wholesale
Wal-Mart
Bayer
Zhejiang Wansheng Pharma
Sichuan Medco Huakang Pharma
Zhendong Anter
DrFormulas
Renata
Dr.R.PFLEGER
DS Healthcare Group

Key Types

Minoxidil
Procapil
Others

Key End-Use

Male
Female
Both

This report can be dispatched within 24-48 Hours.

2015-2025 Global OTC Hair Loss Treatments Market Research

Source

Recent Posts

Hair Loss Treatment Industry Market

Global Medical Hair Replacement Market

/in /by

Global Medical Hair Replacement Market Size, Status and Forecast 2020-2026

Market Analysis and Insights: Global Medical Hair Replacement Market

The global Medical Hair Replacement market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Medical Hair Replacement Scope and Market Size

The medical Hair Replacement market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Medical Hair Replacement market will be able to gain the upper hand as they use the report as a powerful resource.

The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The following players are covered in this report:

Cole Instruments

FotoFinder Systems

Mentok healthcare

ERTIP

Balmain

Hair Dreams

Easihair

Socap

Donna Bella

Cinderella Hair

Hairlocs

Klix Hair Extension

UltraTress

Racoon

Hair Addictionz

FN LONGLOCKS

VivaFemina

Femme Hair Extension

Locks&Bonds

Angel Wings

Godrejcp

Anhui Jinruixiang

Ruimei

Xuchang Penghui

Shengtai

Yinnuohair

Xuchang Haoyuan

Meishang

Yiwu YiLu

Medical Hair Replacement Breakdown Data by Type

Head Hair Transplant

Eyebrow Transplant

Medical Hair Replacement Breakdown Data by Application

Hospitals

Clinics

Global Medical Hair Replacement Market Size, Status and Forecast 2020-2026

Source

Previous Post

Silicon Valley Hair Institute Announces Feature on Yelp’s List of Top 10 Best Bay Area Hair Loss Clinics

Silicon Valley Hair Institute Announces Post on Foster City

/in /by

Silicon Valley Hair Institute Announces Post on Foster City and Easy Access to Hair Transplantation in the Bay Area

Silicon Valley Hair Institute, the Bay Area leader in hair transplantation, is proud to announce a new post on how its Foster City and Palo Alto locations provide easy access for Bay Area consumers interested in hair transplantation, from San Jose to San Mateo to San Francisco.

With many Bay Area consumers “working from home,” more and more are realizing now is an ideal time for a hair transplant to improve their looks.

“The response to our online initial consultation on hair loss has been phenomenal,” explained Miguel Canales, surgeon, and founder of Silicon Valley Hair Institute. “Moreover, our central location in Foster City makes it easy for clients to come for their first in-person consultation or appointment, whether they live in San Francisco, San Mateo, or San Jose.”

The new post can be read at https://siliconvalleyhairinstitute.com/bay-area-fc. It explains that since Foster City is located midway between San Francisco and San Jose and is directly across the bay from Hayward, it is literally at the center of the Bay Area.

Those who would like to investigate and online hair loss consultation can visit the link at https://siliconvalleyhairinstitute.com/virtual. The online consultation form has proved to be very popular, as clients can take the first step from the convenience of their computers or mobile phones.

SKINCARE IS THE NEXT STEP IN A NEW AND IMPROVED LOOK

It should be noted that the Silicon Valley hair Institute focuses on hair transplants but has a sister website that focuses on skincare issues. Many Bay Area consumers want to not only improve their hair by mitigating their hair loss through a hair transplantation, they also want to look younger and have healthier looking skin by using the latest skincare technologies. That website can be visited at https://svaestheticderm.com.

ABOUT SILICON VALLEY HAIR INSTITUTE

Silicon Valley Hair Institute, under the leadership of top-rated California hair transplant surgeon Miguel Canales MD, is one of the best facilities offering San Francisco Bay Area hair transplants.

Dr. Canales provides the full range of advanced hair transplant and hair restoration procedures for Bay Area residents, from San Francisco to San Jose and Foster City. Services include robotic hair transplant systems, San Jose ARTAS hair transplant, and San Jose hair transplant programs.

If one needs a hair loss specialist, look no further than this Bay Area hair transplant center. Dr. Canales also performs female hair transplants for women and eyebrow restoration, thus offering the best hair transplant and robotic hair replacement options.

Silicon Valley Hair Institute Announces Post on Foster City and Easy Access to Hair Transplantation in the Bay Area

Source

Previous Posts

PRP Workshop To Enhance Hair Restoration

PRP for Hair Loss in the Bay Area

/in /by

SVHI PRP Therapy Announces New Post on PRP for Hair Loss in the Bay Area

SHVI PRP Therapy, a Bay Area clinic focused on treatments for PRP (Platelet Rich Plasma) hair loss therapy at https://svhi-prp.com/, is proud to announce a newly updated ‘FAQ’ (Frequently Asked Questions) document on PRP therapy for hair loss, especially in Bay Area communities such as San Mateo, Burlingame, and Foster City.

“Clients often have questions on how PRP works and whether or not it may be effective for hair loss treatment,” explained Miguel Canales, surgeon, and founder of SVHI PRP therapy. “Our FAQ document explains the basics, but we always recommend a client call or come in for a one-on-one consultation.”

Bay Area residents can review the FAQ document at https://svhi-prp.com/faq/.

The document starts off by focusing on the needs and issues of women as the fact of the matter is that women often suffer from hair thinning, and this is often treatable by PRP.

It all depends on the particular situation.

Another option is to visit the company’s sister website, the Silicon Valley Hair Institute, and check out the blog.

Post such as ‘Women Can Lose Their Hair as Well as Men’ at https://siliconvalleyhairinstitute.com/women-can-lose-their-hair-as-well-as-men-and-it-can-be-very-embarrassing/ explain some of the particular issues faced by women as well.

And, finally, persons who want to look their best should extend their efforts beyond their hair and look at their skincare issues; yet another website at https://svaestheticderm.com/ touches on these issues.

Regardless of whether the issue is hair or skin, Dr Miguel Canales offers no-obligation consultations where he can work with a patient, whether male or female, to improve their appearance.

ABOUT SVHI PRP THERAPY

SVHI PRP Therapy (https://svhi-prp.com/) is a Bay Area company based in Foster City, California that offers PRP for hair loss to clients from San Francisco to San Mateo, Palo Alto to Redwood City, Redwood City to Burlingame and beyond.

Clients who are suffering from hair loss and are seeking innovative therapy come to SVHI PRP Therapy to explore their options, including PRP therapy for hair loss.

The company offers a no-obligation consultation on hair loss with Dr. Miguel Canales, a recognized specialist in the hair loss industry, including hair transplantation.

SVHI PRP Therapy Announces New Post on PRP for Hair Loss in the Bay Area

Source

Recent Posts

Stem Cell Alopecia Treatment Market

Stem Cell Alopecia Treatment

/in /by

Global Stem Cell Alopecia Treatment Market By Indication, By Geographic Scope And Forecast

Stem Cell Alopecia Treatment Market Size And Forecast

According to Verified Market Research, The Global Stem Cell Alopecia Treatment Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2019 to 2026.

The Global Stem Cell Alopecia Treatment Market report provides a holistic evaluation of the market for the forecast period (2017–2026). The report comprises of various segments as well an analysis of the trends and factors that are playing a substantial role in the market.

These factors; the market dynamics, involves the drivers, restraints, opportunities, and challenges through which the impact of these factors in the market are outlined.

The drivers and restraints are intrinsic factors whereas opportunities and challenges are extrinsic factors of the market. The Global Stem Cell Alopecia Treatment Market study provides an outlook on the development of the market in terms of revenue throughout the prognosis period.

What is Stem Cell Alopecia Treatment?

Alopecia is an autoimmune skin disease that mainly affects the hair follicles, resulting in hair loss. There are three types of alopecia namely, alopecia areata, alopecia totalis, and alopecia Universalis. Both children and adults of all age groups are capable of acquiring such disease. The stem cell is used as therapy for regenerating hair growth. This approach is minimally invasive and therefore eliminates the need for undergoing surgery. Such treatment is available in hospitals, and dermatology clinics.

Global Stem Cell Alopecia Treatment Market Outlook

In the report, the market outlook section mainly encompasses the fundamental dynamics of the market which include drivers, restraints, opportunities, and challenges faced by the industry. Drivers and restraints are intrinsic factors whereas opportunities and challenges are extrinsic factors of the market.

The market is in demand as people are more concerned about facial appearance and therefore adopting such treatment. The use of such treatment options is utilized more in dermatology clinics than in hospitals. The number of clinics offering the stem-cell alopecia treatment is surging as patients are adopting the minimally invasive way for treatment. The hormonal and nutritional imbalance among adults is driving market growth. Drugs for treating alopecia is already available in the market, but it comes with adverse side effects. Therefore, the market for stem cell alopecia treatment has a future scope.

Verified Market Research narrows down the available data using primary sources to validate the data and use it in compiling a full-fledged market research study. The report contains a quantitative and qualitative estimation of market elements which interests the client. The “Global Stem Cell Alopecia Treatment Market” is mainly bifurcated into sub-segments which can provide classified data regarding the latest trends in the market.

Global Stem Cell Alopecia Treatment Market Competitive Landscape

The “Global Stem Cell Alopecia Treatment Market” study report will provide a valuable insight with an emphasis on global market including some of the major players such as APEX Biologix, Belgravia Center, RepliCel, Riken Research Institute, Kerastem, Sanford Burnham Prebys Medical Discovery Institute. Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Global Stem Cell Alopecia Treatment Market, By Indication

• Male Pattern Baldness
• Female Pattern Baldness
• Others

Global Stem Cell Alopecia Treatment Market Geographic Scope

• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Rest of Asia Pacific
• Rest of the World

Top Trending Reports:

Research Methodology of Verified Market Research:

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post sales analyst support

Global Stem Cell Alopecia Treatment Market By Indication, By Geographic Scope And Forecast

Source

Recent Posts